GLP-1 & Incretin Science

STEP UP: Testing Whether More Dose Means More Effect

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

STEP UP, registered as NCT05646706, was a completed phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults with obesity, three times the standard 2.4 mg weight-management dose. Wharton and colleagues published it in Lancet Diabetes and Endocrinology in November 2025.

Key facts

Registration
NCT05646706
Acronym
STEP UP
Phase
3b
Status
Completed
Enrolment
1,407
Dose tested
7.2 mg once weekly
Standard dose
2.4 mg for weight management
Published
Lancet Diabetes Endocrinol, Nov 2025

Why the question is not obvious

Receptor-mediated effects saturate. Once most receptors are occupied most of the time, adding more drug produces progressively less additional effect while adverse effects, which may follow different dose-response relationships, can continue rising. Whether a higher dose helps is therefore an empirical question about where the curve flattens, not an assumption.

What a phase 3b trial is

Phase 3b studies run after the pivotal trials and often after approval, addressing questions the registration programme did not: a new dose, a new population, a comparison the label does not cover. They are proper randomised trials, and they exist because approval settles fewer questions than it appears to.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why the dose ceiling matters commercially

Semaglutide at 2.4 mg reported 13.7% in the SURMOUNT-5 head-to-head against tirzepatide's 20.2%. If a higher dose closes part of that gap, the competitive position changes without a new molecule. That is a considerably cheaper route to a better number than developing a new compound, which is why the trial was worth running.

The tolerability trade-off

Gastrointestinal adverse effects are the dose-limiting factor across this class, and they follow from GLP-1 receptor pharmacology itself rather than from any impurity or design flaw. Any dose increase has to be read alongside what happened to discontinuation, because a dose producing more weight reduction in those who tolerate it can produce less across everyone assigned to it.

Why this is the estimand question again

This is the situation the efficacy and treatment-policy estimands separate. The efficacy estimand answers what a higher dose does in people who stay on it; the treatment-policy estimand answers what it does across everyone randomised, including those who stopped. A higher dose can improve the first and worsen the second, and a single headline figure conceals which.

What this does not concern

Research material, and it is not dosing guidance for anything. Semaglutide is a licensed medicine and 7.2 mg is a dose arm in a registered trial conducted under clinical supervision. Nothing supplied here is semaglutide or an alternative to it.

Frequently asked questions

Is a higher dose automatically more effective?

No. Receptor-mediated effects saturate, so additional drug produces progressively less additional effect while adverse effects may keep rising.

Why does the estimand matter here?

A higher dose can improve results among those who stay on it while worsening them across everyone randomised, if discontinuation rises.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.